Large intestine-targeted, nanoparticle-releasing oral vaccine to control genitorectal viral infection

Nature Medicine

Volumn 18, Issue 8, 2012, Pages 1291-1296

  Zhu, Qing ^a,b   Talton, James ^c   Zhang, Guofeng ^d   Cunningham, Tshaka ^a   Wang, Zijian ^e   Waters, Robert C ^c   Kirk, James ^c   Eppler, Bärbel ^c   Klinman, Dennis M ^f   Sui, Yongjun ^a   Gagnon, Susan ^a   Belyakov, Igor M ^a,g   Mumper, Russell J ^h   Berzofsky, Jay A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b AIR FORCE GENERAL HOSPITAL   (China)

^c NANO ADM Advanced Development and Manufacturing Center   (United States)

^d NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING   (United States)

^e Jingmeng Research Center   (China)

^f NATIONAL CANCER INSTITUTE   (United States)

^g UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^h University of North Carolina   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EUDRAGIT; NANOPARTICLE; PEPTIDE VACCINE; POLYGLACTIN; TOLL LIKE RECEPTOR; VACCINIA VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; GENITORECTAL VIRUS INFECTION; HUMORAL IMMUNITY; INFECTION CONTROL; LARGE INTESTINE; MOUSE; MUCOSAL IMMUNITY; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; RECTUM MUCOSA; SMALL INTESTINE MUCOSA; VAGINA MUCOSA; VIRAL CLEARANCE; VIRUS INFECTION; VIRUS REPLICATION;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, ORAL; AMINO ACID SEQUENCE; ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; DRUG DELIVERY SYSTEMS; FEMALE; IMMUNITY, MUCOSAL; INTESTINE, LARGE; LACTIC ACID; LIPOPEPTIDES; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; NANOPARTICLES; OLIGODEOXYRIBONUCLEOTIDES; ORGAN SPECIFICITY; OVARY; POLY I-C; POLYGLYCOLIC ACID; POLYMETHACRYLIC ACIDS; RECTUM; SPECIFIC PATHOGEN-FREE ORGANISMS; VACCINES, SUBUNIT; VACCINIA; VACCINIA VIRUS; VAGINA; VIRAL LOAD; VIRAL VACCINES;

ANIMALIA; MUS;

EID: 84864645051     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.2866     Document Type: Article

References (32)

1. + cytotoxic T lymphocytes for resistance to mucosal viral transmission in mice and enhancement of resistance by local administration of IL-12. J. Clin. Invest. 102, 2072-2081 (1998).
2. Belyakov, I.M. et al. Mucosal AIDS vaccine reduces disease and viral load in gut reservoir and blood after mucosal infection of macaques. Nat. Med. 7, 1320-1326 (2001).
3. + T cells. J. Immunol. 178, 7211-7221 (2007).
4. Zhu, Q. et al. Immunization with adenovirus at the large intestinal mucosa as an effective vaccination strategy against sexually transmitted viral infection. Mucosal Immunol. 1, 78-88 (2008).
5. + T-cell responses during chronic infection refect clinical status. PLoS ONE 3, e3577 (2008).
6. Price, G.E. et al. Single-dose mucosal immunization with a candidate universal infuenza vaccine provides rapid protection from virulent H5N1, H3N2 and H1N1 viruses. PLoS ONE 5, e13162 (2010).
7. Schiffer, J.T. et al. Mucosal host immune response predicts the severity and duration of herpes simplex virus-2 genital tract shedding episodes. Proc. Natl. Acad. Sci. USA 107, 18973-18978 (2010).
8. + T-cell responses are common to blood and gastrointestinal mucosa, and Gag-specifc responses dominate in rectal mucosa of HIV controllers. J. Virol. 84, 10354-10365 (2010).
9. Lehner, T. et al. Protective mucosal immunity elicited by targeted iliac lymph node immunization with a subunit SIV envelope and core vaccine in macaques. Nat. Med. 2, 767-775 (1996).
10. Miller, C.J. & McGhee, J.R. Progress towards a vaccine to prevent sexual transmission of HIV. Nat. Med. 2, 751-752 (1996).
11. Boyer, J.D. et al. Protection against simian/human immunodefciency virus (SHIV) 89.6P in macaques after coimmunization with SHIV antigen and IL-15 plasmid. Proc. Natl. Acad. Sci. USA 104, 18648-18653 (2007).
12. van Ginkel, F.W., Jackson, R.J., Yuki, Y. & McGhee, J.R. Cutting edge: the mucosal adjuvant cholera toxin redirects vaccine proteins into olfactory tissues. J. Immunol. 165, 4778-4782 (2000).
13. McConnell, E.L., Basit, A.W. & Murdan, S. Colonic antigen administration induces signifcantly higher humoral levels of colonic and vaginal IgA, and serum IgG compared to oral administration. Vaccine 26, 639-646 (2008).
14. O'Hagan, D.T., Singh, M. & Ulmer, J.B. Microparticle-based technologies for vaccines. Methods 40, 10-19 (2006).
15. Mundargi, R.C., Babu, V.R., Rangaswamy, V., Patel, P. & Aminabhavi, T.M. Nano/micro technologies for delivering macromolecular therapeutics using poly(D, L-lactide-co-glycolide) and its derivatives. J. Control. Release 125, 193-209 (2008).
16. Desai, M.P., Labhasetwar, V., Amidon, G.L. & Levy, R.J. Gastrointestinal uptake of biodegradable microparticles: effect of particle size. Pharm. Res. 13, 1838-1845 (1996).
17. Trinchieri, G. & Sher, A. Cooperation of Toll-like receptor signals in innate immune defence. Nat. Rev. Immunol. 7, 179-190 (2007).
18. Manicassamy, S. & Pulendran, B. Modulation of adaptive immunity with Toll-like receptors. Semin. Immunol. 21, 185-193 (2009).
19. Zhu, Q. et al. Toll-like receptor ligands synergize through distinct dendritic cell pathways to induce T cell responses: implications for vaccines. Proc. Natl. Acad. Sci. USA 105, 16260-16265 (2008).
20. Zhu, Q. et al. Using 3 TLR ligands as a combination adjuvant induces qualitative changes in T cell responses needed for antiviral protection in mice. J. Clin. Invest. 120, 607-616 (2010).
21. Bott, C. et al. In vivo evaluation of a novel pH-And time-based multiunit colonic drug delivery system. Aliment. Pharmacol. Ther. 20, 347-353 (2004).
22. Hooper, J.W., Custer, D.M., Schmaljohn, C.S. & Schmaljohn, A.L. DNA vaccination with vaccinia virus L1R and A33R genes protects mice against a lethal poxvirus challenge. Virology 266, 329-339 (2000).
23. Fogg, C. et al. Protective immunity to vaccinia virus induced by vaccination with multiple recombinant outer membrane proteins of intracellular and extracellular virions. J. Virol. 78, 10230-10237 (2004).
24. Hooper, J.W., Custer, D.M. & Thompson, E. Four-gene-combination DNA vaccine protects mice against a lethal vaccinia virus challenge and elicits appropriate antibody responses in nonhuman primates. Virology 306, 181-195 (2003).
25. Pasare, C. & Medzhitov, R. Control of B-cell responses by Toll-like receptors. Nature 438, 364-368 (2005).
26. Gururajan, M., Jacob, J. & Pulendran, B. Toll-like receptor expression and responsiveness of distinct murine splenic and mucosal B-cell subsets. PLoS ONE 2, e863 (2007).
27. Shang, L. et al. Toll-like receptor signaling in small intestinal epithelium promotes B-cell recruitment and IgA production in lamina propria. Gastroenterology 135, 529-538 (2008).
28. Rassa, J.C., Meyers, J.L., Zhang, Y., Kudaravalli, R. & Ross, S.R. Murine retroviruses activate B cells via interaction with Toll-like receptor 4. Proc. Natl. Acad. Sci. USA 99, 2281-2286 (2002).
29. Cronkhite, R.I. & Michael, J.G. Sub-compartmentalization of the gastrointestinal (GI) immune system determined with microbeads that differ in release properties. Vaccine 22, 2106-2115 (2004).
30. Cole, E.T. et al. Enteric coated HPMC capsules designed to achieve intestinal targeting. Int. J. Pharm. 231, 83-95 (2002).
31. Schellekens, R.C. et al. Pulsatile drug delivery to ileo-colonic segments by structured incorporation of disintegrants in pH-responsive polymer coatings. J. Control. Release 132, 91-98 (2008).
32. Han, M. et al. In vitro and in vivo evaluation of a novel capsule for colon-specifc drug delivery. J. Pharm. Sci. 98, 2626-2635 (2009).